Table 2.
Description | FDR | Description | FDR | ||||
---|---|---|---|---|---|---|---|
miR-9-5p | KEGG | Focal adhesion | 0.021 | miR-124-3p | KEGG | Apelin signaling pathway | 0.012 |
Prostate cancer | 0.021 | Cellular senescence | 0.012 | ||||
ErbB signaling pathway | 0.021 | Axon guidance | 0.012 | ||||
Cellular senescence | 0.021 | Pathways in cancer | 0.012 | ||||
Regulation of actin cytoskeleton | 0.021 | Panther | x | ||||
MicroRNAs in cancer | 0.021 | Reactome | Receptor-type tyrosine-protein phosphatases | 0.031 | |||
Neurotrophin signaling pathway | 0.021 | NOTCH2 Activation and Transmission of Signal to the Nucleus | 0.031 | ||||
Hepatocellular carcinoma | 0.021 | Semaphorin interactions | 0.031 | ||||
Panther | Ras Pathway | 0.009 | Signaling by Receptor Tyrosine Kinases | 0.031 | |||
Reactome | X | Signaling by MET | 0.031 | ||||
MiR-21-5p | KEGG | Proteoglycans in cancer | 0.019 | MiR-138-5p | KEGG | X | |
Ras signaling pathway | 0.032 | Panther | X | ||||
MicroRNAs in cancer | 0.038 | Reactome | X | ||||
Neurotrophin signaling pathway | 0.043 | MiR-1-3p | KEGG | MicroRNAs in cancer | 0.000 | ||
EGFR tyrosine kinase inhibitor resistance | 0.043 | Adherens junction | 0.010 | ||||
Panther | X | Bacterial invasion of epithelial cells | 0.010 | ||||
Reactome | Signaling by NTRK2 (TRKB) | 2.62 × 10−3 | Axon guidance | 0.029 | |||
Signaling by NTRKs | 2.62 × 10−3 | Proteoglycans in cancer | 0.029 | ||||
Signaling by BMP | 2.69 × 10−3 | EGFR tyrosine kinase inhibitor resistance | 0.035 | ||||
Signaling by Receptor Tyrosine Kinases | 4.94 × 10−3 | Choline metabolism in cancer | 0.035 | ||||
MET activates PI3K/AKT signaling | 4.94 × 10−3 | Regulation of actin cytoskeleton | 0.035 | ||||
PI-3K cascade:FGFR3 | 5.14 × 10−3 | Hepatitis B | 0.035 | ||||
PI-3K cascade:FGFR4 | 5.97 × 10−3 | Cocaine addiction | 0.042 | ||||
Signaling by FGFR3 | 5.97 × 10−3 | Viral carcinogenesis | 0.042 | ||||
Signaling by FGFR4 | 5.97 × 10−3 | Renal cell carcinoma | 0.042 | ||||
Signaling by EGFR | 5.97 × 10−3 | Hippo signaling pathway | 0.042 | ||||
Signaling by FGFR3 in disease | 5.97 × 10−3 | Spliceosome | 0.043 | ||||
Signaling by FGFR3 point mutants in cancer | 5.97 × 10−3 | Human papillomavirus infection | 0.044 | ||||
PI-3K cascade:FGFR2 | 6.63 × 10−3 | Thyroid cancer | 0.044 | ||||
Downstream signaling of activated FGFR3 | 8.67 × 10−3 | Cellular senescence | 0.044 | ||||
Signaling by FGFR3 fusions in cancer | 9.29 × 10−3 | Pathogenic Escherichia coli infection | 0.044 | ||||
Signaling by FGFR1 | 9.29 × 10−3 | Panther | X | ||||
Downstream signaling of activated FGFR4 | 9.77 × 10−3 | Reactome | Signaling by Receptor Tyrosine Kinases | 0.000 | |||
Signaling by FGFR4 in disease | 0.010 | Clathrin-mediated endocytosis | 0.010 | ||||
GAB1 signalosome | 0.010 | RHO GTPases Activate WASPs and WAVEs | 0.010 | ||||
PIP3 activates AKT signaling | 0.010 | Signaling by VEGF | 0.013 | ||||
Downstream signaling of activated FGFR2 | 0.012 | RNA Polymerase II Transcription | 0.028 | ||||
Signaling by FGFR in disease | 0.020 | VEGFA-VEGFR2 Pathway | 0.028 | ||||
Intracellular signaling by second messengers | 0.022 | Gene expression (Transcription) | 0.035 | ||||
MAPK family signaling cascades | 0.022 | Signaling by RAS mutants | 0.035 | ||||
Signaling by TGF-beta family members | 0.022 | Diseases of signal transduction | 0.035 | ||||
Signaling by FGFR1 in disease | 0.025 | EPH-Ephrin signaling | 0.041 | ||||
Interleukin-4 and Interleukin-13 signaling | 0.028 | Generic Transcription Pathway | 0.041 | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | 0.028 | Platelet activation, signaling and aggregation | 0.042 | ||||
Signaling by FGFR2 | 0.031 | RHO GTPase Effectors | 0.042 | ||||
Signaling by FGFR2 in disease | 0.034 | EPHB-mediated forward signaling | 0.042 | ||||
Diseases of signal transduction | 0.034 | Hemostasis | 0.045 | ||||
Generic Transcription Pathway | 0.035 | Regulation of actin dynamics for phagocytic cup formation | 0.048 | ||||
PI3K Cascade | 0.035 | Membrane Trafficking | 0.049 | ||||
Signaling by NODAL | 0.038 | ||||||
Gene expression (Transcription) | 0.038 | ||||||
MET activates PTPN11 | 0.039 | ||||||
PI-3K cascade:FGFR1 | 0.040 | ||||||
IRS-mediated signalling | 0.042 |
Pathways directly involved in cancer are marked in bold. Each miRNA section is separated by color. X—no results obtained. KEKEGG, Pa—Panther, ReReactome.